Skip to main content
●+254 119 023975 support@dnalabskenya.com
Patient Portal LoginB2B / Doctor Portal
DNA LabsKenya
Medical information Clinical review pending

Genetic Testing

PDGFRA Gene PDGFRA Selective Sequencing of Exons 12 14 and 18 Genetic Test

This genetic test identifies specific mutations in the PDGFRA gene (exons 12, 14, and 18) associated with certain cancers, using Next Generation Sequencing (NGS) technology. Results can help guide personalized treatment options.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or tumour tissue sample. Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for a blood sample. If a tissue sample is needed, your doctor will provide specific instructions. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the PDGFRA Gene PDGFRA Selective Sequencing of Exons 12 14 and 18 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us
01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients diagnosed with cancers suspected to be associated with PDGFRA mutations.
  • ✓Individuals with a personal or family history of cancers linked to PDGFRA mutations.
  • ✓Patients whose cancer may benefit from targeted therapy based on PDGFRA status.
  • ✓Research purposes related to cancer genetics.
02

In plain language

What this test helps you understand

This test helps identify specific mutations in the PDGFRA gene that may be driving cancer growth. This information can assist healthcare providers in selecting targeted therapies, understanding prognosis, and potentially identifying individuals at higher risk.
The PDGFRA Gene Selective Sequencing test is a specialized genetic analysis designed to detect mutations within specific parts (exons 12, 14, and 18) of the PDGFRA gene. Mutations in this gene are linked to the development and progression of certain types of cancer. This test utilizes advanced Next Generation Sequencing (NGS) technology for accurate detection of these genetic alterations. Understanding these mutations can provide valuable information for oncologists to tailor treatment strategies and potentially improve patient outcomes. This test is part of our comprehensive genetic testing services available across Kenya.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for a blood sample. If a tissue sample is needed, your doctor will provide specific instructions. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube) or tumour tissue sample. Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) of the specified exons of the PDGFRA gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only analyzes specific exons (12, 14, and 18) of the PDGFRA gene. It may not detect mutations in other parts of the gene or in other genes associated with cancer. Results are based on the sample provided and may be affected by sample quality. This test does not guarantee a specific outcome or response to treatment.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

PDGFRA is a gene that provides instructions for making a protein involved in cell growth and division. Mutations in this gene can contribute to the development of certain cancers.
This test specifically looks for mutations in exons 12, 14, and 18 of the PDGFRA gene using Next Generation Sequencing (NGS) technology.
Identifying specific PDGFRA mutations can help doctors understand the genetic basis of a patient's cancer and guide decisions about targeted therapies.
A sample is typically collected via a blood draw or from tumour tissue. Your doctor will advise on the appropriate sample type.
Turnaround time varies. Please contact the laboratory for current estimates.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Beta CTx Beta Crosslaps Collagen Type 1 C-Telopeptide Test

The Beta CTx test measures bone resorption markers to help assess bone health and osteoporosis risk.

Learn more →

Bcell Rearrangement Detection Test

The Bcell Rearrangement Detection Test helps diagnose leukemia by identifying genetic changes in B cells. It's a key tool for hematologists and oncologists.

Learn more →

Dpd Gene Mutations 5Fu Toxicity Detection Test

This genetic test identifies mutations in the DPD gene, helping predict the risk of severe side effects from the chemotherapy drug 5-fluorouracil (5FU).

Learn more →

Ganciclovir Resistance Detection Test

This test checks for genetic changes in the cytomegalovirus (CMV) that may make it resistant to the antiviral medication Ganciclovir. It helps guide treatment decisions, especially for patients with weakened immune systems.

Learn more →
Chat on WhatsApp